当前位置:首页 - 行情中心 - 圣达生物(603079) - 财务分析 - 利润表

圣达生物

(603079)

  

流通市值:18.68亿  总市值:18.68亿
流通股本:1.71亿   总股本:1.71亿

利润表

报告期2024-03-312023-12-312023-09-302023-06-30
公司类型通用通用通用通用
一、营业总收入184,829,589.97727,405,727.98544,108,238.57363,030,169.14
营业收入184,829,589.97727,405,727.98544,108,238.57363,030,169.14
二、营业总成本177,350,467.11729,017,572.14540,121,562.64360,973,727.49
营业成本147,712,333.89610,950,920.09448,560,622.83299,999,717.38
税金及附加2,246,979.869,412,757.496,829,085.894,159,225.09
销售费用2,769,640.3914,202,679.439,701,900.576,643,297.52
管理费用17,751,626.761,963,343.5253,340,853.5835,634,672.43
研发费用7,896,868.6842,924,788.0830,185,572.7821,215,566.61
财务费用-1,026,982.41-10,436,916.47-8,496,473.01-6,678,751.54
其中:利息费用573,615.971,537,370.09948,161.9413,680.23
其中:利息收入1,272,144.088,406,832.625,331,880.323,520,574.9
加:公允价值变动收益-100.8828,842.7417,522.74
加:投资收益1,691,249.12406,508735,390.44677,250.44
资产处置收益-202,167.26301,709.18301,709.18
资产减值损失(新)-2,710,357.73-50,809,509.26-4,833,083.94-5,272,837.1
信用减值损失(新)-856,530.56-3,160,793.13-1,120,701.14-1,685,618.62
其他收益1,902,018.69,297,391.117,041,530.094,758,027.38
营业利润平衡项目0000
四、营业利润7,505,502.29-45,675,979.36,140,363.3852,495.67
加:营业外收入65,902.382,990,530.65635,201.4300,226.73
减:营业外支出2,659.372,622,277.721,713,630.241,098,350.38
利润总额平衡项目0000
五、利润总额7,568,745.3-45,307,726.375,061,934.4654,372.02
减:所得税费用2,264,864.288,893,963.777,688,631.776,104,215.19
六、净利润5,303,881.02-54,201,690.14-2,626,697.31-6,049,843.17
持续经营净利润5,303,881.02-54,201,690.14-2,626,697.31-6,049,843.17
归属于母公司股东的净利润3,813,060.72-54,062,928.21-3,687,796.57-6,332,992.3
少数股东损益1,490,820.3-138,761.931,061,099.26283,149.13
(一)基本每股收益0.02-0.32-0.02-0.04
(二)稀释每股收益0.02-0.32-0.02-0.04
九、综合收益总额5,303,881.02-54,201,690.14-2,626,697.31-6,049,843.17
归属于母公司股东的综合收益总额3,813,060.72-54,062,928.21-3,687,796.57-6,332,992.3
归属于少数股东的综合收益总额1,490,820.3-138,761.931,061,099.26283,149.13
公告日期2024-04-202024-04-202023-10-282023-08-26
审计意见(境内)标准无保留意见
TOP↑